Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Alice Watson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alice Watson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

S09 E09: Boehringer’s Christoph von der Goltz on setbacks and success in R&D

22:08
 
Share
 

Manage episode 474575536 series 3299609
Content provided by Alice Watson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alice Watson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

How can pharmaceutical companies best navigate setbacks in drug development to deliver breakthroughs in R&D? Find out in this week’s episode, where Isabel and Jade share an interview with Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim.

Together, he and Jade explore the ins and outs of drug failure, whether to pivot or persevere after an R&D setback, how to better break the stigma of mental illness and much more.

A little more on EMJ GOLD’s guest…

Christoph von der Goltz is Global Head of Medicine Central Nervous System and Emerging Areas at Boehringer Ingelheim. He has more than 15 years of experience in a variety of roles in pharmaceutical R&D. He is also a board-certified psychiatrist with more than 10 years of clinical experience in neurology and psychiatry and academic research in preclinical, clinical and public health projects in Germany and Sweden.

  continue reading

295 episodes

Artwork
iconShare
 
Manage episode 474575536 series 3299609
Content provided by Alice Watson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alice Watson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

How can pharmaceutical companies best navigate setbacks in drug development to deliver breakthroughs in R&D? Find out in this week’s episode, where Isabel and Jade share an interview with Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim.

Together, he and Jade explore the ins and outs of drug failure, whether to pivot or persevere after an R&D setback, how to better break the stigma of mental illness and much more.

A little more on EMJ GOLD’s guest…

Christoph von der Goltz is Global Head of Medicine Central Nervous System and Emerging Areas at Boehringer Ingelheim. He has more than 15 years of experience in a variety of roles in pharmaceutical R&D. He is also a board-certified psychiatrist with more than 10 years of clinical experience in neurology and psychiatry and academic research in preclinical, clinical and public health projects in Germany and Sweden.

  continue reading

295 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play